2-Cyclopropyl-5-methyl-1,3,4-oxadiazole | 1797986-19-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Cyclopropyl-5-methyl-1,3,4-oxadiazole
• CAS: 1797986-19-6
• 化学式: C₆H₈N₂O
• 分子量: 124.14
• InChiKey: ICKNOXRPEGEVKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] METHODS FOR USING TRIAZOLO-PYRAZINYL SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISORDERS<br/>[FR] PROCÉDÉS D'UTILISATION D'ACTIVATEURS DE LA GUANYLATE CYCLASE SOLUBLE DANS LA TRIAZOLO-PYRAZINYLE POUR DES TROUBLES FIBROTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2017200857A1

  公开（公告）日：2017-11-23

  Provided are methods for treating or preventing a fibrotic disease selected from systemic sclerosis, cystic fibrosis, non-alcoholic steatohepatitis, Peyronie's disease, or interstitial lung disease; the method comprising administering a therapeutically effective amount of a compound of Formula (I) (wherein R1, R2, R3, R4, and R5 are as herein described) or a pharmaceutically acceptable salt thereof, to a patient in need of such therapy.

  提供了治疗或预防纤维化疾病的方法，所述疾病包括系统性硬化症、囊性纤维化、非酒精性脂肪肝炎、佩罗尼病或间质性肺病；该方法包括向需要此类治疗的患者施用化合物I式（其中R1、R2、R3、R4和R5如本文所述）或其药用可接受盐的治疗有效量。
• [EN] IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS<br/>[FR] DÉRIVÉS D'IMIDAZO-PYRAZINE UTILES EN TANT QU'ACTIVATEURS DE GUANYLATE CYCLASES SOLUBLES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015187470A1

  公开（公告）日：2015-12-10

  A compound of Formula II or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ("cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula II, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula II or a pharmaceutically acceptable salt thereof.

  公式II的化合物或其药学上可接受的盐，能够调节体内环鸟苷酸单磷酸（"cGMP"）的产生，并且通常适用于治疗和预防与紊乱的cGMP平衡相关的疾病。此外，本发明还涉及制备公式II的化合物或其药学上可接受的盐的方法，用于治疗和预防上述疾病，并为此目的制备药物，以及包含公式II的化合物或其药学上可接受的盐的药物制剂。
• FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS
  申请人：HANDOK INC.

  公开号：US20160168156A1

  公开（公告）日：2016-06-16

  The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases. In some compounds of Formula I, Q is —CH═CR 3 C(O)NR 4 R 5 , —C≡CC(O)NR 4 R 5 , or

  该披露提供了由化学式I或其药用可接受的盐、溶剂化合物、多型体、酯、互变异构体或前药表示的新型化合物。这些化合物可用作Trk的抑制剂，并且在治疗疼痛、癌症、炎症、神经退行性疾病和某些传染病方面是有用的。 在化合物I的某些化合物中，Q为—CH═CR3C(O)NR4R5，—C≡CC(O)NR4R5，或...
• [EN] MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE<br/>[FR] MODULATEURS D'INDOLAMINE 2,3-DIOXYGÉNASE
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD

  公开号：WO2017051354A1

  公开（公告）日：2017-03-30

  Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the progression of AIDS and general immunosuppression.

  提供了这些化合物及其药用盐，它们的药物组合物，它们的制备方法，以及它们在预防和/或治疗HIV方面的使用方法；包括预防AIDS的进展和一般免疫抑制。
• [EN] DIACYLGLYCEROL KINASE MODULATING COMPOUNDS<br/>[FR] COMPOSÉS MODULANT LA DIACYLGLYCÉROL KINASE
  申请人：CARNA BIOSCIENCES INC

  公开号：WO2021130638A1

  公开（公告）日：2021-07-01

  The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

  本公开提供了调节二酰基甘油激酶的化合物以及用于治疗癌症（包括实体瘤）和病毒感染（如HIV或乙型肝炎病毒感染）的药物组合物。这些化合物可以单独使用或与其他药物联合使用。